

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

RESIGNATION OF SUPERVISOR AND PROPOSED APPOINTMENT OF SUPERVISOR

RESIGNATION OF SUPERVISOR AND PROPOSED APPOINTMENT OF SUPERVISOR

Recently, the Supervisory Committee of the Company received a resignation letter from Mr. Cao Genxing who reported to the Supervisory Committee to resign as a supervisor of the Company due to his age. Mr. Cao will continue acting as a supervisor of the Company until the appointment of a new supervisor is approved by the Shareholders at a general meeting.

The Supervisory Committee is pleased to announce the proposed appointment of Mr. Chen Bing as a supervisor of the Company subject to the approval by Shareholders at a general meeting.

CIRCULAR

A circular, containing, among others, further details regarding the proposed appointment of Mr. Chen as a supervisor of the Company and a notice of the general meeting will be dispatched to the Shareholders in due course.

RESIGNATION OF SUPERVISOR

Recently, the supervisory committee (the “**Supervisory Committee**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) received a resignation letter from Mr. Cao Genxing (“**Mr. Cao**”) who reported to the Supervisory Committee to resign as a supervisor of the Company due to his age.

As the resignation of Mr. Cao will result in the number of members of the Supervisory Committee to fall below the statutory minimum level, Mr. Cao will continue acting as a supervisor of the Company until the appointment of a new supervisor is approved by the shareholders of the Company (the “**Shareholders**”) at a general meeting.

Mr. Cao has confirmed that there is no disagreement between him and the Supervisory Committee and/or the Company during his term of office and there is no matter relating to his resignation that needs to be brought to the attention of the Shareholders.

The Company hereby expresses its gratitude to Mr. Cao for his valuable contribution during his term of office.

PROPOSED APPOINTMENT OF SUPERVISOR

The Supervisory Committee is pleased to announce the proposed appointment of Mr. Chen Bing (“**Mr. Chen**”) as a supervisor of the Company. The proposed appointment of Mr. Chen is subject to the approval of Shareholders at a general meeting.

The biographical details of Mr. Chen are set out as follows:

Mr. Chen, aged 48. From September 1997 to August 2005, Mr. Chen served at KPMG. From April 2006 to August 2008, he served as a senior audit manager of MAZARS Shanghai Certified Public Accountants LLP* (上海瑪澤會計師事務所(普通合夥)), and from August 2008 to July 2017, as its partner. From July 2017 to December 2021, he served various positions including the joint general manager of the audit department, assistant to the president and senior assistant to the president of Fosun International Limited, a company listed on The Stock Exchange of Hong Kong Limited (the “**HKSE**”) (stock code: 00656) (“**Fosun International**”). From January 2022, he has served as a vice president, the co-chief risk officer and the general manager of the audit department of Fosun International. Mr. Chen currently serves as a non-executive director of BabyTree Group, a company listed on the HKSE (stock code: 01761) and a director and supervisor of certain subsidiaries of Fosun International. Mr. Chen is a non-practicing member of the Chinese Institute of Certified Public Accountants and a member of Shanghai Institute of Certified Public Accountants. Mr. Chen obtained his bachelor’s degree in economics from Fudan University in July 1997.

As at the date of this announcement, Mr. Chen has not entered into a service contract with the Company as a supervisor. Mr. Chen will not receive any remuneration from the Company as a supervisor. The relevant supervisor service contract will not provide for a specific remuneration amount. The appointment of Mr. Chen as a supervisor of the Company will be effective upon the approval of Shareholders at a general meeting and end on the expiration of the term of the ninth session of the Supervisory Committee.

Mr. Chen has confirmed that, save as disclosed above, as at the date of this announcement, he does not have any relationship with any directors (the “**Directors**”), other supervisors, senior management or substantial or controlling shareholders of the Company, and does not hold any other positions in the Company or any subsidiaries of the Company nor any directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

As at the date of this announcement, Mr. Chen does not have any interests or short positions in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. There are no other matters concerning the proposed appointment of Mr. Chen that need to be brought to the attention of the Shareholders.

CIRCULAR

A circular, containing, among others, further details regarding the proposed appointment of Mr. Chen as a supervisor of the Company and a notice of the general meeting will be dispatched to the Shareholders in due course.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, People's Republic of China

27 March 2023

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *For identification purposes only*